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Abstract

Background: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired,
generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated
the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD.
Materials and Methods: This analysis included three 24-week, double-blind, placebo-controlled studies of
flibanserin 100 mg each bedtime (qhs) in premenopausal women, a similarly designed study in postmenopausal
women, and a 52-week, open-label extension study in premenopausal women.
Results: In a pooled analysis of premenopausal women, mean baseline body mass index (BMI) was 27.0 kg/m2 in
the flibanserin group (n = 1227) and 26.8 kg/m2 in the placebo group (n = 1238). Among patients who completed
24 weeks of treatment, least squares (LS) mean weight change was -1.4 kg in the flibanserin group (n = 1010) and
-0.1 kg in the placebo group (n = 1066; p < 0.0001). Weight loss ‡5% from baseline was reported in 21.0% of
patients who received flibanserin and 7.8% of patients who received placebo; weight loss ‡10% was reported in
3.8% and 2.0% of patients, respectively. In postmenopausal women, mean baseline BMI was 27.7 kg/m2 in the
flibanserin group (n = 467) and 27.3 kg/m2 in the placebo group (n = 480). LS mean weight change at week 24
was -1.8 kg in the flibanserin group (n = 385) and -0.1 kg in the placebo group (n = 425; p < 0.0001), with weight
loss ‡5% reported in 24.7% and 7.3% of patients, respectively, and weight loss ‡10% reported in 5.2% and 1.7%,
respectively. In HSDD patients with >12 months (n = 880) and >18 months (n = 637) of exposure to flibanserin,
mean weight change was -1.0 and -1.2 kg, respectively; 25.4% and 26.9% of patients, respectively, experienced
weight loss ‡5% from baseline, and 7.8% and 8.4%, respectively, experienced weight loss ‡10%.
Conclusions: Women treated with flibanserin for HSDD may experience weight loss.
Keywords: body weight, flibanserin, reproductive health, sexuality, weight loss
functioning) in premenopausal women and is the only U.S.
Food and Drug Administration (FDA)-approved treatment
for HSDD.1,2 Flibanserin is a postsynaptic 5-HT1A agonist
and 5-HT2A antagonist that has been shown to induce decreases in serotonin and increases in dopamine and norepinephrine in certain regions of the cerebral cortex.3–6

Introduction

F

libanserin is indicated for the treatment of acquired,
generalized hypoactive sexual desire disorder (HSDD;
not limited to certain types of stimulation, situation, or
partner and developed after a period of normal sexual
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By modulating these neurotransmitters, flibanserin is hypothesized to restore balance to the activity of excitatory and
inhibitory influences on the regulation of a healthy sexual
response.7,8 The efficacy and safety of flibanserin in the
treatment of HSDD have been demonstrated in randomized clinical trials of premenopausal and postmenopausal
women9–13; however, flibanserin is not approved by the
FDA for use in postmenopausal women.
Serotonin neurons play a complex role in the regulation of
weight and metabolism, and pharmacologic agents with
serotonin-related activity have been shown to increase or
decrease body weight.14–19 Some serotonergic medications
(e.g., certain selective serotonin reuptake inhibitors [SSRIs])
are associated with weight gain.20,21 However, the selective
5-HT2C agonist lorcaserin is an FDA-approved weight-loss
treatment for patients who are obese (body mass index [BMI]
‡30 kg/m2) or overweight (BMI ‡27 kg/m2 in the presence of
‡1 weight-related comorbid condition, such as hypertension
or type 2 diabetes).22 The receptor binding profile of flibanserin suggests that it may have an impact on body weight
as well.
Data collected in the clinical development program for
flibanserin were utilized to retrospectively investigate the
effect of flibanserin treatment on body weight in women with
HSDD. Analyses included change in body weight associated
with flibanserin in premenopausal women (pooled data from
three randomized, placebo-controlled, 24-week trials9–11)
and postmenopausal women (in a randomized, placebocontrolled, 24-week study13), and during long-term flibanserin use (in a 52-week, open-label, extension study23).

Materials and Methods
Study design and participants

This retrospective analysis included data from five
studies from the flibanserin clinical development program
in HSDD (Table 1).9–11,13,23 Study conduct was in compliance with the principles of the Declaration of Helsinki
(1996) in accordance with the International Conference on
Harmonisation Good Clinical Practice guidelines. All study
protocols were approved by an institutional review board or
independent ethics committee, and all participants provided
written informed consent before the initiation of study
procedures.
Three patient populations were included in this analysis:
(1) premenopausal women ‡18 years old who were diagnosed with HSDD and enrolled in one of three
randomized, double-blind, placebo-controlled trials
that evaluated the safety and efficacy of flibanserin
(study names: VIOLET, DAISY, BEGONIA)9–11;
(2) naturally postmenopausal women of any age who were
diagnosed with HSDD and enrolled in a randomized,
double-blind, placebo-controlled trial evaluating the
safety and efficacy of flibanserin (SNOWDROP)13; and
(3) premenopausal women ‡18 years old who were diagnosed with HSDD and had participated in a randomized placebo-controlled trial (VIOLET, DAISY,
DAHLIA),9,10 a randomized withdrawal study (ROSE),12
or a pharmacokinetic study of flibanserin and were
subsequently enrolled in a 52-week, open-label extension study (SUNFLOWER).23

Table 1. Studies Included in This Analysis
Study name
VIOLET

9

Dates and locations
July 2006 to April 2008

Study design

Participants

24-Week R, DB,
PBO study

Premenopausal
women ‡18 years,
DSM-IV-TR diagnosis
of HSDD

24-Week R, DB,
PBO study

Premenopausal
women ‡18 years,
DSM-IV-TR
diagnosis of HSDD

Premenopausal
women ‡18 years,
DSM-IV-TR
diagnosis of HSDD
Naturally postmenopausal
women, DSM-IV-TR
diagnosis of HSDD
Premenopausal
women ‡18 years,
DSM-IV-TR
diagnosis of HSDD

NCT00360529

54 Sites in United States
and Canada

DAISY10

July 2006 to March 2008

NCT00360555

77 Sites in United States
and Canada

BEGONIA11

October 2009 to
February 2011
75 Sites in United States

24-Week R, DB,
PBO study

October 2009 to
March 2011
75 Sites in United States
March 2007
to August 2009
201 Sites in United States
and Canada

24-Week R, DB,
PBO study

NCT00996164
SNOWDROP13
NCT00996372
SUNFLOWER23
NCT00441558

a

52-Week
OLE study

Study medication
Flibanserin 50 mg
qhs (n = 295)a
Flibanserin 100 mg
qhs (n = 290)
Placebo (n = 295)
Flibanserin 25 mg
bid (n = 396)a
Flibanserin 50 mg
bid (n = 392)a
Flibanserin 100 mg
qhs (n = 395)
Placebo (n = 398)
Flibanserin 100 mg
qhs (n = 542)
Placebo (n = 545)
Flibanserin 100 mg
qhs (n = 467)
Placebo (n = 480)
Flibanserin 50
or 100 mg
qhs or 25 or 50 mg
bid flexibly dosed
(n = 1723 overall)

Analyses of the placebo-controlled studies excluded patients who received flibanserin at doses other than 100 mg qhs.
bid, twice daily; DB, double-blind; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision;
HSDD, hypoactive sexual desire disorder; OLE, open-label extension; PBO, placebo-controlled; qhs, each bedtime; R, randomized.
Data from Derogatis et al.,9 Thorp et al.,10 Katz et al.,11 Simon et al.,13 and Jayne et al.23 Additional information not found in these
sources is from original study data.
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The inclusion criteria for all studies in this analysis required that participants were diagnosed with generalized
acquired HSDD of ‡24 weeks’ duration (or ‡6 months’ duration for the SNOWDROP study) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR) criteria.
Key exclusion criteria included other sexual dysfunctions;
major depressive disorder within the previous 6 months;
history of suicidal ideation or behavior; pelvic inflammatory
disease, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy; current pregnancy or pregnancy within the last month
(SUNFLOWER23 study) or last 6 months (VIOLET,9 DAISY,10
and BEGONIA studies); a history of cancer within the last 10
years; or blood abnormalities.
Use of certain medications was prohibited, including
sex hormones (except for hormonal contraceptives in premenopausal women and systemic hormone therapy in postmenopausal women), dopamine agonists, benzodiazepines,
prescription hypnotics, antidepressants, antipsychotics, mood
stabilizers, antiepileptics, St. John’s wort, metoclopramide, or
chronically used narcotics.11,13,23 None of the studies in this
analysis excluded patients on the basis of weight or BMI.
Patients received double-blind flibanserin or placebo in the
24-week randomized controlled trials and open-label flibanserin
in the 52-week extension study. To obtain information about
weight change associated with the recommended dose of flibanserin (100 mg each bedtime [qhs]), analyses of the placebocontrolled trials included only those patients treated with
flibanserin 100 mg qhs or placebo. The long-term, open-label
study enrolled patients from a variety of flibanserin dosing
regimens (and some patients previously on placebo). All patients received flibanserin 50 mg qhs for 4 weeks, with flexible
dosing thereafter to optimize efficacy and tolerability; permitted
doses were 50 or 100 mg qhs, or 25 or 50 mg twice per day.
None of the studies in this analysis was designed to evaluate weight loss as a clinical benefit of flibanserin treatment;
body weight was measured to assess weight loss and weight
gain as potential adverse effects.
Statistical analyses

The analysis population for the 24-week placebocontrolled trials consisted of patients who were randomly
assigned to treatment, received at least one dose of study
medication, and had at least one assessment of body weight.
For the three 24-week studies of premenopausal women,
patient-level data were pooled by treatment group (flibanserin 100 mg qhs vs. placebo) for assessments of body
weight at baseline, and weeks 8, 16, and 24.
In the premenopausal and postmenopausal patient populations, least-squares (LS) mean change in body weight from
baseline to week 24 was compared for flibanserin versus
placebo using analysis of covariance (ANCOVA) models
with treatment group as a factor and baseline body weight as a
covariate. In the premenopausal patient population, additional ANCOVA models were used to explore the effect of
potential confounding variables (i.e., use of SSRIs or serotonin norepinephrine reuptake inhibitors [SNRIs], smoking
status, baseline BMI level [£25 or >25 kg/m2], hormonal
contraceptive use, and responder status on HSDD efficacy
measures) on weight change.

3

In each model, except that for BMI level, the variable of
interest and treatment group were used as factors with
baseline body weight as a covariate; because BMI and weight
are highly correlated, the model for BMI included baseline
BMI (rather than baseline weight) as the covariate.
The analysis population for ANCOVAs of HSDD responder status consisted of patients in the overall analysis
population who had at least one postbaseline efficacy assessment. To identify patients with a clinically meaningful benefit
in HSDD symptoms, change from baseline to endpoint on
measures of sexual functioning (i.e., number of satisfying
sexual events [SSE], the Female Sexual Functioning Indexdesire domain [FSFI-D], and the Female Sexual Distress
Scale-Revised-desire item [FSDS-R13]) was anchored to responses on the Patient Global Impression of Improvement
(PGI-I) scale. For each measure of sexual functioning, a responder was defined as a patient with baseline to endpoint
score change greater than the corresponding minimal response
threshold (i.e., score of 3 [minimally improved]) on the PGI-I.
In the open-label extension study, change in body weight
was assessed for patients who had >12 months (365 days) and
>18 months (547 days) of exposure to flibanserin.
Results
Patients

Demographic and clinical characteristics of premenopausal and postmenopausal women treated with flibanserin
100 mg qhs or placebo in a 24-week randomized controlled
trial are shown in Table 2. In the pooled analysis of premenopausal women, 1210 patients in the flibanserin group
and 1218 patients in the placebo group had at least 1 assessment of body weight and were included in this analysis.
In the study of postmenopausal women, 467 flibanserintreated patients and 479 patients receiving placebo had at
least 1 assessment of body weight and were included in this
analysis. Within the premenopausal and postmenopausal
patient populations, characteristics were similar in the flibanserin and placebo groups. In the long-term, open-label
extension study, 880 patients received flibanserin for >12
months and 637 patients received flibanserin for >18 months.
Change in weight after 24 weeks of treatment
with flibanserin

At week 24, LS mean change (standard error) in weight was
-1.4 (0.1) kg in the flibanserin group and -0.1 (0.1) kg in the
placebo group in premenopausal women ( p < 0.0001) and -1.8
(0.2) kg in the flibanserin group and -0.1 (0.2) kg in the placebo group in postmenopausal women ( p < 0.0001) (Fig. 1).
Weight loss differed significantly by BMI in the premenopausal patient population; greater LS mean weight loss was
observed in women with higher (>25 kg/m2) versus lower
baseline BMI ( p < 0.01) (Table 3).
None of the other baseline factors investigated (i.e., SSRI/
SNRI use, smoking status, and hormonal contraceptive use)
had a significant effect on weight change, after accounting for the effects of baseline body weight and treatment
group. Similarly, there was no significant difference between
treatment responders and nonresponders (as determined
by change on HSDD efficacy measures [number of SSE,

Table 2. Demographic and Baseline Clinical Characteristics and Selected Concomitant
Medications in 24-Week Randomized Controlled Studies (All Treated Population)
Premenopausal womena
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Characteristics
Age, years, mean (SD)
Race, n (%)
White
Black/African American
Asian
Other
Hispanic ethnicity, n (%)
Duration of HSDD, months, mean (SD)
Weight, kg, mean (SD)
BMI, kg/m2, mean (SD)
BMI category (kg/m2), n (%)
Underweight (<18.5)
Normal (18.5 to <25)
Overweight (25 to <30)
Obese (‡30)
Current smoker, n (%)
Selected concomitant medications
Hormonal contraceptive use, n (%)
Systemic hormone therapy, n (%)
SSRI/SNRI use, n (%)d

Postmenopausal women

Flibanserin
100 mg qhs (n = 1227)

Placebo
(n = 1238)

Flibanserin
100 mg qhs (n = 467)

35.9 (7.5)

36.2 (7.3)

55.4 (5.4)

55.5 (5.3)

1073
131
20
3
117
53.9
73.6
27.0

(87.4)
(10.7)
(1.6)
(0.2)
(9.5)
(42.6)
(18.0)
(6.2)

1089
119
21
9
111
57.0
72.9
26.8

(88.0)
(9.6)
(1.7)
(0.7)
(9.0)
(47.1)
(17.3)
(6.5)

425
35
4
3
28
59.5
74.3
27.7

(91.0)
(7.5)
(0.9)
(0.6)
(6.0)
(46.0)
(15.4)
(5.7)

444
27
4
5
23
61.6
73.2
27.3

(92.5)
(5.6)
(0.8)
(1.0)
(4.8)
(51.3)b
(15.1)b
(5.4)c

21
559
330
313
159

(1.7)
(45.6)
(26.9)
(25.5)
(13.0)

23
569
341
301
157

(1.9)
(46.0)
(27.5)
(24.3)
(12.7)

2
164
165
133
53

(0.4)
(35.3)
(35.6)
(28.7)
(11.3)

7
175
161
134
55

(1.5)
(36.7)
(33.8)
(28.1)
(11.5)

489 (41.1)
—
47 (2.0)

487 (41.0)
—
21 (1.7)

a

—
74 (15.9)
12 (2.8)

Placebo
(n = 480)

—
74 (15.4)
12 (2.7)

Three studies (VIOLET, DAISY, and BEGONIA) pooled.
n = 479.
n = 477.
d
Protocol violation.
BMI, body mass index; SD, standard deviation; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor.
b
c

FIG. 1. Mean change from
baseline weight (kg) after 8, 16,
and 24 weeks of treatment with
flibanserin 100 mg qhs or placebo in (A) premenopausal women and (B) postmenopausal
women. Mean (SD) baseline
weight was 73.7 (17.9) kg in the
flibanserin group and 73.1 (17.4)
kg in the placebo group for
premenopausal women, and
74.4 (15.4) kg in the flibanserin
group and 73.4 (15.2) kg in the
placebo group for postmenopausal women. Error bars represent –1 standard error.
*p < 0.0001; {p < 0.005. qhs,
each bedtime; SD, standard
deviation.
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Table 3. Subgroup Analysis of Change
in Body Weight for Selected Baseline
Characteristics and Treatment Response
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Variable

N

SSRI/SNRI useb
Yes
49
No
2331
Current smoker
Yes
159
No
1148
Baseline BMI
£25 kg/m2
1157
>25 kg/m2
1263
Hormonal contraceptive use
Yes
523
No
784
Treatment response
SSE
Yes
471
No
812
FSFI-D
Yes
495
No
810
FSDS-R13
Yes
610
No
696

-1.6 (0.5)
-0.7 (0.1)

0.0861

-0.7 (0.3)
-0.7 (0.1)

0.9405

-0.5 (0.1)
-1.0 (0.1)

0.0015

HSDD who received flibanserin 50 mg qhs (in the VIOLET
study).9 For flibanserin 50 mg qhs, LS mean weight change at
week 24 was -0.6 kg (compared with -0.1 kg for placebo and
-1.4 kg for flibanserin 100 mg); weight loss of ‡5% and ‡10%
was experienced by 8.9% and 1.9% of women, respectively
(compared with 7.8% and 2.0%, respectively, for placebo and
21.0% and 3.8%, respectively, for flibanserin 100 mg).
Nausea, a common adverse event with flibanserin, was
assessed as a possible contributor to weight loss. However,
the incidence of nausea in premenopausal women with HSDD
who received flibanserin 100 mg in the 24-week randomized,
placebo-controlled trials was somewhat higher (7.1%) in women with weight loss <5% compared with 5.8% in women
with weight loss ‡5%. The incidence of nausea was similar in
postmenopausal women with weight loss <5% versus weight
loss ‡5% (incidence of nausea 5.3% and 5.6%, respectively).

-0.8 (0.1)
-0.6 (0.1)

0.4883

Change in weight after longer term treatment
with flibanserin

-0.8 (0.1)
-0.6 (0.1)

0.3303

-0.7 (0.1)
-0.7 (0.1)

0.8016

-0.7 (0.1)
-0.7 (0.1)

0.9961

LS mean
(SE) change
in body
weight (kg)

pa

a
p Value for the contrast between the two levels of each variable,
after accounting for the effects of baseline body weight (or baseline
BMI in the model for BMI level) and treatment group.
b
Protocol violation.
FSDS-R13, Female Sexual Distress Scale-Revised-desire item;
FSFI-D, Female Sexual Function Index-desire domain; LS, least
squares; SE, standard error; SSE, satisfying sexual events.

FSFI-D score, FSDS-R13 score]) in change from baseline
body weight.
In each analysis, there was a statistically significant association of weight change at week 24 with baseline body
weight and treatment group such that higher baseline body
weight and treatment with flibanserin (vs. placebo) were associated with greater weight loss.
At the end of 24 weeks, 21.0% of premenopausal women
receiving flibanserin had lost ‡5% of their baseline body
weight compared with 7.8% of premenopausal women receiving placebo ( p < 0.0001); 3.8% and 2.0% of patients, respectively, experienced ‡10% weight loss (Fig. 2). Similarly,
24.7% of postmenopausal women receiving flibanserin had
lost ‡5% of their baseline body weight at week 24, compared
with 7.3% of postmenopausal women receiving placebo
( p < 0.0001); 5.2% and 1.7% of patients, respectively, experienced ‡10% weight loss. At week 24, weight gain ‡7% (the
FDA definition of significant weight gain24) was observed in
1.8% and 3.4% of premenopausal women in the flibanserin
and placebo groups, respectively, and in 2.1% and 2.8% of
postmenopausal women, respectively.
To evaluate a possible dose–response effect, an analysis
of once-daily flibanserin at a dose lower than currently
recommended included 295 premenopausal women with

In addition, weight loss was observed after 12 and 18
months of treatment with flibanserin (Table 4). In premenopausal patients, mean (standard deviation) weight change
from parent study baseline equaled -1.0 (6.1) kg in patients
with flibanserin exposure >12 months and -1.2 (5.4) kg in
patients with flibanserin exposure >18 months. Weight loss
>5% from parent study baseline was observed in 25.4% of patients with >12 months of treatment with flibanserin and 26.9%
of patients with >18 months of treatment; weight loss ‡10%
was experienced by 7.8% and 8.4% of patients, respectively.
Discussion

In this retrospective analysis of clinical studies, flibanserin
was associated with statistically significant weight loss
compared with placebo in both premenopausal and postmenopausal women with HSDD who received 6 months of
double-blind treatment. In addition, flibanserin-associated
weight loss was comparable in both premenopausal and
postmenopausal women. Also, there was no evidence of
weight regain based on the assessment of patients treated
with flibanserin for 18 months. Hormonal contraceptive use,
SSRI/SNRI use, BMI level, and smoking status (assessed at
baseline); nausea (assessed as an adverse event); and treatment responder status (based on clinically meaningful change
in HSDD efficacy measures) did not demonstrate a significant
effect on weight change.
The patients with HSDD who participated in these clinical
trials of flibanserin were not selected for overweight or
obesity, nor did they enter the studies with the goal of losing
weight. In the patients with HSDD included in this analysis,
baseline BMI ranged from underweight to obese, with rates
of overweight (premenopausal women, 27.2%; postmenopausal women, 34.4%) and obesity (premenopausal women,
24.9%; postmenopausal women, 28.2%) somewhat lower
than currently observed in the general population of adult
women in the United States,25 which may represent a healthy
user type bias in these clinical trials. Nonetheless, comparing
these findings with studies of FDA-approved weight-loss
drugs may provide some context regarding the magnitude of
weight loss observed.
In double-blind, placebo-controlled studies of FDA-approved
weight-loss drugs (i.e., lorcaserin, naltrexone/bupropion,
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FIG. 2. Proportion of patients who
lost 5% or more, 7% or more, and 10%
or more of their baseline body weight
after 24 weeks of treatment with
flibanserin 100 mg qhs or placebo
in (A) premenopausal women and
(B) postmenopausal women.
*p < 0.0001; {p < 0.05; {p < 0.01.

Table 4. Change from Baseline Body Weight
After at Least 12 and 18 Months of Treatment
with Flibanserin

Parameter

Exposure >12 Exposure >18
months
months
(n = 880)
(n = 637)

Baseline mean (SD) weight 73.2 (18.0)
73.6
in parent study, kg
Baseline mean (SD) weight 73.0 (18.2)
73.3
in open-label study, kg
Mean (SD) change from
-1.0 (6.1)
-1.2
parent study baseline
to final study visit, kg
-0.8 (5.3)
-0.9
Mean (SD) change from
open-label study baseline
to final study visit, kg
Percent change from parent study baseline
to final study visit, n (%)
Weight loss ‡5%
198 (25.4)
166
Weight loss ‡7%
133 (17.0)
111
Weight loss ‡10%
61 (7.8)
52
Weight gain ‡7%
68 (8.7)
54
Percent change from open-label study baseline
to final study visit, n (%)
Weight loss ‡5%
153 (19.5)
129
Weight loss ‡7%
91 (11.6)
80
Weight loss ‡10%
39 (5.0)
34
Weight gain ‡7%
43 (5.5)
39

(18.4)
(18.7)
(5.4)
(4.4)

(26.9)
(18.0)
(8.4)
(8.7)
(20.7)
(12.9)
(5.5)
(6.3)

Results at baseline and final study visit include all patients with
nonmissing data.

phentermine/topiramate, and liraglutide), patients received
dietary and exercise counseling, in addition to medication.
Mean weight loss in overweight/obese patients (70%–85% of
whom were women) ranged from 5 to 10 kg for the active
study medication and 1 to 3 kg for placebo after 52 to 56
weeks of treatment.22,26–31 Studies that reported mean weight
change at interim time points showed similar weight loss at
24–28 weeks and at 52–56 weeks.26,28,31
Between 40% and 70% of patients treated with FDAapproved weight-loss medications (and 16%–27% of patients
receiving placebo) lost ‡5% of their baseline body weight at
the typical month-12 study endpoint.22,26–31 In these studies
of women with HSDD, mean baseline BMI (premenopausal
women, 26.9 kg/m2; postmenopausal women, 27.5 kg/m2)
was substantially lower than that in studies of weight-loss
medications (35.8–38.3 kg/m2); in addition, HSDD patients
were generally not attempting to lose weight and did not
receive the ancillary therapies provided in weight-loss studies
(e.g., nutritional counseling, exercise counseling).26–31
The lower BMI in these studies, as well as the lack of
patient intent to lose weight, makes the weight loss in the
flibanserin-treated patients all the more intriguing. Mean
weight loss was 1.5–1.8 kg after 6 months of treatment with
flibanserin and 1.0 kg after 12 months of treatment, with
mean weight remaining essentially unchanged in patients
who received placebo. Weight loss ‡5% from baseline was
observed at month 6 in 21%–25% of patients receiving flibanserin and only 7%–8% of patients receiving placebo, and
at month 12 in 25% of flibanserin-treated patients. It is possible that weight loss observed in the flibanserin studies was
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limited by a floor effect, since baseline weight was lower in
these studies compared with clinical trials of weight-loss
medications.
The mechanism(s) of action by which flibanserin produces
weight loss are currently unknown. The receptor binding
affinity of flibanserin is highest for 5-HT1A receptors (as
an agonist) and 5-HT2A receptors (as an antagonist).6 Both
5-HT1A agonist activity and 5-HT2A antagonist activity result
in the inhibition of glutamate neurons, thereby reducing
serotonin release in the prefrontal cortex.6
The complex role of serotonin in mammalian energy balance has not been completely elucidated at this time.32 Based
on evidence from numerous studies of the serotonin system, it
is generally understood that enhanced serotonergic neurotransmission is associated with suppression of food intake
and reduction in body weight.19,26,32 However, mirtazapine,
an atypical antidepressant with agonist effects at the 5-HT1A
receptor and antagonist effects at the 5-HT2A receptor (similar to flibanserin), is generally known to cause weight
gain.33,34 Furthermore, flibanserin is a minor 5-HT2C receptor
antagonist,1 yet the 5-HT2C receptor agonist lorcaserin has
been approved as a weight-loss drug.22 Thus, the serotoninrelated activity of flibanserin does not appear to explain the
observed weight loss in this analysis of patients treated with
flibanserin.32
Either flibanserin affects body weight via a serotoninbased process that is as yet unknown or weight loss associated
with flibanserin can be accounted for by non–serotoninrelated mechanisms (e.g., enhanced cortical norepinephrine
release). It is interesting to note that no significant association
was observed in this analysis for weight loss and treatment
response (defined as clinically meaningful change on HSDD
efficacy measures), suggesting that the flibanserin mechanism of action for weight loss may differ from that for improved sexual function.
This analysis has several limitations. The studies included
in this analysis were designed to evaluate the efficacy and
safety of flibanserin for the treatment of women with HSDD.
This analysis of change in body weight is, therefore, post hoc
and exploratory in nature. There was no systematic attempt
to collect information about the use of medications or supplements known to affect body weight or participation
in programs intended to promote weight loss, nor was dietary or exercise counseling provided. Because this analysis
included only observed cases, weight change was not assessed in patients who discontinued early from the underlying studies. Further investigation is needed to more
rigorously evaluate changes in body weight associated with
flibanserin treatment.
Conclusions

This retrospective analysis showed that treatment with
flibanserin 100 mg qhs in women with HSDD was associated
with statistically significant weight loss compared with placebo in both premenopausal and postmenopausal patients.
Weight loss without apparent weight regain was also observed during longer term, open-label flibanserin treatment of
up to 18 months. In contrast to more typical serotonergic
antidepressants, weight gain does not appear to be a clinical
concern with flibanserin. Women treated with flibanserin for
HSDD may experience weight loss.
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